DCM
DAFNA Capital Management Portfolio holdings
AUM
$362M
This Quarter Return
+32.6%
1 Year Return
-0.48%
3 Year Return
+117.01%
5 Year Return
+181.93%
10 Year Return
+1,483.26%
AUM
$439M
AUM Growth
+$439M
(+5.3%)
Cap. Flow
-$48.1M
Cap. Flow
% of AUM
-10.96%
Top 10 Holdings %
Top 10 Hldgs %
49.48%
Holding
86
New
10
Increased
12
Reduced
30
Closed
14
Top Buys
| 1 |
AtriCure
ATRC
|
$4.43M |
| 2 |
Perspective Therapeutics
CATX
|
$3.69M |
| 3 |
Insulet
PODD
|
$2.73M |
| 4 |
Larimar Therapeutics
LRMR
|
$2.52M |
| 5 |
KalVista Pharmaceuticals
KALV
|
$2.44M |
Top Sells
| 1 |
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
|
$15.2M |
| 2 |
IMGN
Immunogen Inc
IMGN
|
$5.74M |
| 3 |
SAGE
Sage Therapeutics
SAGE
|
$5.31M |
| 4 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$5.25M |
| 5 |
SPDR S&P Biotech ETF
XBI
|
$5.01M |
Sector Composition
| 1 | Healthcare | 86.43% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
SPDR S&P Biotech ETF
XBI
$5.07B
| $40.9M | 9.31% | 431,215 -52,785 | -11% | -$5.01M |
|
2
Stereotaxis
STXS
$261M
| $35.7M | 8.13% | 13,680,554 | – | – |
|
3
Cytokinetics
CYTK
$4.23B
| $27.9M | 6.35% | 398,100 -1,900 | -0.5% | -$133K |
|
4
IDEAYA Biosciences
IDYA
$2.15B
| $19.6M | 4.46% | 446,341 -70,000 | -14% | -$3.07M |
|
5
Merus
MRUS
$4.98B
| $17.1M | 3.89% | 378,995 -75,875 | -17% | -$3.42M |
|
6
Revolution Medicines
RVMD
$7.1B
| $16.5M | 3.76% | 511,894 | – | – |
|
7
Viking Therapeutics
VKTX
$3.04B
| $15.9M | 3.62% | 194,117 -54,100 | -22% | -$4.44M |
|
8
Syndax Pharmaceuticals
SNDX
$1.41B
| $15.7M | 3.57% | 659,574 -83,000 | -11% | -$1.98M |
|
9
iShares Biotechnology ETF
IBB
$5.6B
| $14.1M | 3.2% | 102,500 | – | – |
|
10
Ascendis Pharma
ASND
$11.8B
| $14M | 3.18% | 92,472 -31,000 | -25% | -$4.69M |
|
11
Xenon Pharmaceuticals
XENE
$2.98B
| $11.8M | 2.68% | 273,739 -3,000 | -1% | -$129K |
|
12
Day One Biopharmaceuticals
DAWN
$769M
| $11M | 2.51% | 666,463 -20,000 | -3% | -$330K |
|
|
BPMC
13
DELISTED
Blueprint Medicines
BPMC
| $10.1M | 2.31% | 106,763 -4,100 | -4% | -$389K |
|
14
Neurocrine Biosciences
NBIX
$13.8B
| $9.88M | 2.25% | 71,615 -1,000 | -1% | -$138K |
|
|
15
KalVista Pharmaceuticals
KALV
$678M
| $9.57M | 2.18% | 806,973 +205,941 | +34% | +$2.44M |
|
16
Tandem Diabetes Care
TNDM
$845M
| $9.14M | 2.08% | 258,208 +37,500 | +17% | +$1.33M |
|
17
DexCom
DXCM
$29.5B
| $9.09M | 2.07% | 65,552 -2,000 | -3% | -$277K |
|
18
Kura Oncology
KURA
$686M
| $8.8M | 2% | 412,663 -80,021 | -16% | -$1.71M |
|
|
19
AtriCure
ATRC
$1.84B
| $8.24M | 1.88% | 271,029 +145,500 | +116% | +$4.43M |
|
|
MORF
20
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $8.16M | 1.86% | 231,748 | – | – |
|
21
Axogen
AXGN
$743M
| $7.55M | 1.72% | 935,894 | – | – |
|
22
Biohaven
BHVN
$1.63B
| $6.49M | 1.48% | 118,730 -50,042 | -30% | -$2.74M |
|
|
TSVT
23
DELISTED
2seventy bio
TSVT
| $6.44M | 1.47% | 1,204,051 -243,414 | -17% | -$1.3M |
|
24
Edgewise Therapeutics
EWTX
$1.51B
| $5.59M | 1.27% | 306,197 -143,187 | -32% | -$2.61M |
|
25
Alector
ALEC
$238M
| $5.5M | 1.25% | 912,928 +303,023 | +50% | +$1.82M |
|